Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$5.05 USD
-0.04 (-0.80%)
Updated Aug 6, 2025 03:59 PM ET
After-Market: $5.21 +0.16 (3.18%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Acurx Pharmaceuticals, Inc.'s return on equity, or ROE, is -526.78% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.08%. While this shows that ACXP has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ACXP 5.05 -0.04(-0.80%)
Will ACXP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACXP
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year?
Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y
ACXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
Other News for ACXP
ACXP Trading Halted as Acurx Pharmaceuticals Awaits News
Acurx Pharmaceuticals trading halted, news pending
Acurx (ACXP) Implements 1-for-20 Reverse Stock Split to Maintain Nasdaq Listing
Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split | ACXP Stock News
Acurx approves 1-for-20 reverse stock split